Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2660)
05/02/2025
Indication
In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed deat...
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with national guidance
Formulation
25mg/mL concentrate for solution for infusion